IN PARTNERSHIP


clinical trials globally increases supply chain efficiencies and reduces drug costs. As the number of clinical trials in emerging markets increases, the demand for reference drugs, or comparators, is mounting.


T


The US and Europe are the biggest clinical trial markets in the world, and the fierce competition between drug manufacturers to get their products to market first is intensifying. Clinical trial sponsors are therefore turning to emerging markets to source comparators efficiently and cost-effectively. Increased demand puts comparator sourcing professionals under immense pressure to source enough quantities of comparator products within the right time frames and budget restrictions. At Clinical Services International (CSI), as a


he prevalence of clinical trials in emerging markets is soaring. With the right infrastructure in place, conducting


leading global comparator sourcing partner, we understand the benefits and risks involved in comparator sourcing in emerging markets for global clinical trials.


Comparator studies Comparator studies aim to prove the efficacy of new or investigational drugs compared to the existing standard of care, also known as the comparator. To ensure treatments are effective before seeking approval and going to market, it is necessary to securely source comparators including reference-listed drugs (RLD) and non-investigational medicinal products (NIMPs) on a global scale.


Pharmaceutical companies and contract research organisations (CROs) must have robust comparator sourcing strategies in place to ensure that comparator drugs are supplied to clinical trial sites without disruption. Working


16 | Clinical Trial Supply Handbook


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92